Non-formulary mirabegron (MYRBETRIQ) will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of overactive bladder (including urinary urgency, urinary frequency and urge incontinence) on the problem list;

-AND–

- If no diagnosis of dementia:
  - Documented treatment failure, intolerance or contraindication to at least two (2) anticholinergic agents (e.g., oxybutynin, trospium, or tolterodine); –OR–

- If diagnosis of dementia or receiving medications (e.g., acetylcholinesterase inhibitor or NMDA receptor antagonist)
  - Documented treatment failure, intolerance or contraindication to Oxytrol TDS

-OR–

- Dose change: Patient previously met criteria and is already taking the drug.

Dosing:
- 25 mg once daily with or without food. Efficacy seen within 8 weeks.
- May increase to 50 mg once daily after 8 weeks based on efficacy and tolerability.
- Do not exceed 25 mg/day in patients with GFR 15-29 mL/min or moderate hepatic impairment (Child-Pugh class B)